House panel curbs comparative-effectiveness research

The healthcare reform bill approved last week by the House Energy and Commerce Committee contained an amendment prohibiting the federal government from using comparative-effectiveness research to “deny or ration care.”

Rep. Michael Rogers, R-Mich., who sponsored the amendment , criticized the pre-amendment language in the bill for containing “no restriction on how the federal government can use this research.

“This is a dangerous open-door policy that will almost certainly lead to comparative-effectiveness research being used to make coverage decisions,” Rogers said.

Comparative-effectiveness research is designed to help identify treatment options that are most effective for a given condition, and the Obama Administration has latched on to it as a strategy in its efforts to reform the U.S. healthcare system.

Rogers, in presenting his amendment, said the federal government cannot be allowed “to use a calculator or a bureaucratic standard to get between patients and doctors.

"Comparative-effectiveness research is about general average assumptions,” Rogers said. “It can’t determine anything about individual patients with a unique condition looking for a unique treatment.”

Some Democrats on the committee objected to the amendment, with several arguing that the term “deny” was too strong. “To deny care when we find out a procedure is harmful is something we would want the federal government to do,” argued Rep. Henry Waxman, D-Calif., chairman of the committee. Despite his opposition, the amendment passed on a voice vote.

The Senate also is considering comparative-effectiveness research in its healthcare reform efforts. Senate Finance Committee Chairman Max Baucus, D-Mont., and Senate Budget Committee Chairman Kent Conrad, D-N.D., introduced legislation that would establish a private, nonprofit corporation that will research and compare clinical outcomes of alternative therapies and healthcare strategies.

The language in the Baucus-Conrad bill requires the Centers for Medicare and Medicaid Services (CMS) to meet several requirements before allowing the use of any research, including comparative-effectiveness research, to be used to make coverage decisions.
Michael Bassett,

Contributor

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.